Printer Friendly

NeoChord Names Martin to its Board of Directors.

M2 PHARMA-April 4, 2016-NeoChord Names Martin to its Board of Directors

(C)2016 M2 COMMUNICATIONS

- US-based medical technology company NeoChord has appointed J. Alex Martin to its board of directors, the company said on Monday.

Most recently, Martin was the president and CEO of Coherex Medical, where he led the company to a successful exit with Biosense Webster (a Johnson and Johnson Co), in November 2015.

Prior to Coherex, Martin was the president and CEO of WorldHeart Corp., where he led the company to a successful exit with HeartWare in August 2012.

Previously, Martin has held senior leadership roles with Edwards Lifesciences, Cordis Corp. (a Johnson and Johnson company), and SonaMed Corp.

Based in St. Louis Park, Minn., NeoChord, Inc. is a privately held medical technology company specialised in the minimally invasive repair of DMitral regurgitation is a progressive disease that can result in atrial fibrillation, congestive heart failure, and death when left untreated.

NeoChord received CE market clearance in December 2012 for the DS1000 system for minimally invasive mitral valve repair of degenerative mitral regurgitation without the use of cardiopulmonary bypass.

To date, over 350 patients have been treated.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2016 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2016 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Apr 4, 2016
Words:201
Previous Article:Study: St. Jude Medical CardioMEMS HF System Effective in Improving Heart Failure Management.
Next Article:Trice Medical Names Hawkins to its Board of Directors.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters